The University of Chicago Header Logo

Connection

Walter M. Stadler to Infusions, Intravenous

This is a "connection" page, showing publications Walter M. Stadler has written about Infusions, Intravenous.
Connection Strength

0.624
  1. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94.
    View in: PubMed
    Score: 0.068
  2. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun; 5(1):57-60.
    View in: PubMed
    Score: 0.063
  3. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7.
    View in: PubMed
    Score: 0.056
  4. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
    View in: PubMed
    Score: 0.054
  5. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1629-36.
    View in: PubMed
    Score: 0.049
  6. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9.
    View in: PubMed
    Score: 0.048
  7. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002 Jan; 13(1):116-20.
    View in: PubMed
    Score: 0.047
  8. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000 Jun; 18(12):2419-26.
    View in: PubMed
    Score: 0.042
  9. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7.
    View in: PubMed
    Score: 0.042
  10. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. Cancer Chemother Pharmacol. 1992; 31(3):213-6.
    View in: PubMed
    Score: 0.023
  11. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
    View in: PubMed
    Score: 0.022
  12. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.021
  13. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr; 25(2):181-5.
    View in: PubMed
    Score: 0.016
  14. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005 May; 95(7):963-8.
    View in: PubMed
    Score: 0.015
  15. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
    View in: PubMed
    Score: 0.015
  16. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
    View in: PubMed
    Score: 0.014
  17. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.011
  18. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.011
  19. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996 Feb; 47(2):194-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.